Understanding Biliary Tract Cancer Treatments and Survival Rates

Biliary tract cancer (BTC) is a rare and often deadly disease that's usually found at an advanced stage. The standard first-line treatment is a combination of gemcitabine and cisplatin. However, there's no clear global standard for second-line treatments after chemotherapy. New therapies targeting specific mutations are changing the treatment landscape, though. Researchers looked at data from a large database to understand treatment patterns and survival rates for patients with advanced or metastatic BTC between 2010 and 2015. They found that less than half of patients started systemic therapy within 90 days of diagnosis.

The most common event after diagnosis was starting first-line therapy, and after that, many patients died. The survival time varied widely, ranging from 5 months to nearly 10 months, depending on the type of second-line treatment. The duration of therapy also varied, from less than a month for some treatments to nearly 4 months for first-line gemcitabine plus cisplatin therapy. Overall, survival was poor and influenced by factors like age, sex, disease stage, health issues, and poverty. There wasn't a clear second-line treatment for patients who didn't have targetable mutations.

Actions